Endeavor Biomedicines' Series A Round

Endeavor Biomedicines raised a round of funding on January 07, 2021.

Endeavor Biomedicines develops treatments targeting the underlying causes of pulmonary fibrosis. The company is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that…

Articles about Endeavor Biomedicines' Series A Round: